Get the Stockscreener App
61.75
0.85%
0.52
After Hours:
61.75
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $61.75, with a volume of 2.15M.
It is up +0.85% in the last 24 hours and down -16.04% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$61.23
Open:
$61.1
24h Volume:
2.15M
Relative Volume:
2.01
Market Cap:
$9.76B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
65.69
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
-4.88%
1M Performance:
-16.04%
6M Performance:
-16.54%
1Y Performance:
-16.07%
1-Day Range:
$60.94
$61.97
1-Week Range:
$60.94
$66.47
52-Week Range:
$60.94
$85.57
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
61.75 | 9.76B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Ieq Capital LLC Lowers Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Handelsbanken Fonder AB Has $3.19 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Principal Financial Group Inc. - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Lowers Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Weitz Partners III Opportunity Fund Added Bio-Techne Corporation (TECH) to its Portfolio - Yahoo Finance
Is the Market Bullish or Bearish on Bio-Techne? - Benzinga
Bio-Techne Co. (NASDAQ:TECH) Shares Acquired by Hahn Capital Management LLC - MarketBeat
Bank of New York Mellon Corp Sells 11,006 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Corp. to Host Earnings Call - ACCESS Newswire
Techne Corp stock hits 52-week low at $61.16 amid market shifts - Investing.com Canada
Techne Corp stock hits 52-week low at $61.16 amid market shifts By Investing.com - Investing.com South Africa
Gene Prediction Tools Market Analysis Report 2025-2030, with Bio-Techne, Charles River Laboratories, Eurofins, GenScript, Danaher, MedGenome, Sino Biological, Syngene & Twist Bioscience - Yahoo Finance
Bio-Techne to Present at Investor Conferences - Yahoo Finance
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu - MSN
Capillary Electrophoresis Market Report 2025-2030, with Profiles of Bio-Rad Laboratories, Bio-Techne, Qiagen, Helena Laboratories, Agilent Technologies, PerkinElmer, Danaher, Merck, Shimadzu & more - Yahoo Finance
New York State Common Retirement Fund Has $39.19 Million Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne (NASDAQ:TECH) Rating Lowered to Neutral at Robert W. Baird - MarketBeat
Pembroke Management LTD Cuts Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Expands RNAscope Probes For Human And Mouse Transcriptome In Spatial Biology - Nasdaq
Bio-Techne Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial Biology - Quantisnow
70,000 RNA Probes Now Available: A Game-Changer for Spatial Biology Research? - StockTitan
Deep Dive Into Bio-Techne Stock: Analyst Perspectives (4 Ratings) - Benzinga
Bio-Techne downgraded to Neutral from Outperform at Baird - TipRanks
Bio-Techne launches GMP TcBuster for cell therapy development By Investing.com - Investing.com Nigeria
Bio-Techne director Amy Herr sells $122,690 in stock By Investing.com - Investing.com Nigeria
Bio-Techne director Amy Herr sells $122,690 in stock - Investing.com India
Bio-Techne Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart
Bio-Techne Stock Outlook: Is Wall Street Bullish or Bearish? - Inkl
Bio-Techne's (NASDAQ:TECH) Soft Earnings Don't Show The Whole Picture - Yahoo Finance
Bio-Techne launches GMP TcBuster for cell therapy development - Investing.com India
Game-Changing Cell Therapy Breakthrough: Bio-Techne's New GMP System Slashes Production Time and Costs - StockTitan
Mirae Asset Global Investments Co. Ltd. Increases Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Earnings call transcript: Bio-Techne Q4 2024 beats EPS forecast By Investing.com - Investing.com Nigeria
Allspring Global Investments Holdings LLC Has $52.64 Million Stake in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Q4 Earnings Estimate for Bio-Techne Issued By William Blair - MarketBeat
Earnings call transcript: Bio-Techne Q4 2024 beats EPS forecast - Investing.com
Q4 EPS Estimates for Bio-Techne Decreased by Leerink Partnrs - MarketBeat
Bio-Techne (NASDAQ:TECH) Shares Gap DownHere's What Happened - MarketBeat
Brokerages Set Bio-Techne Co. (NASDAQ:TECH) Price Target at $86.57 - MarketBeat
4,474 Shares in Bio-Techne Co. (NASDAQ:TECH) Bought by Summit Trail Advisors LLC - MarketBeat
Bio-Techne Co. (NASDAQ:TECH) Position Reduced by State of Alaska Department of Revenue - MarketBeat
Stephens Investment Management Group LLC Has $52.92 Million Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Corporation: How Spatial Biology and Molecular Diagnostics Are Changing the Game! - Smartkarma
Ex-Dividend Reminder: Cencora, Bio-Techne and Eli Lilly - Nasdaq
Bio-Techne Corp. stock underperforms Monday when compared to competitors - MSN
Bio-Techne Co. (NASDAQ:TECH) Shares Acquired by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bio Techne Corp Stock (TECH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Herr Amy E. | Director |
Feb 14 '25 |
Sale |
65.96 |
1,860 |
122,691 |
1,976 |
0.22%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):